NEXGEL, INC.

Contributing Author

Recent Articles by NEXGEL, INC.

Aug-20	NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE NXGL NXGL -14.79% GlobeNewswire
Aug-17	NEXGEL Reports Second Quarter 2026 Financial Results NXGL -33.54% GlobeNewswire
Jun-04	NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th -18th NXGL GlobeNewswire
May-19	NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration NXGL +20.14% GlobeNewswire
May-13	NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical NXGL -8.10% GlobeNewswire
May-12	NEXGEL To Report First Quarter 2026 Financial Results on May 15th NXGL GlobeNewswire
May-06	NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience, to Board of Directors NXGL GlobeNewswire
Apr-27	NEXGEL Appoints Ian Blackman as Chief Financial Officer NXGL -6.04% GlobeNewswire
Apr-21	NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment NXGL +15.89% GlobeNewswire
Apr-17	NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET NXGL GlobeNewswire
Apr-15	NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction NXGL +27.12% NXGL -15.26% GlobeNewswire
Apr-08	NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction NXGL GlobeNewswire
Mar-31	NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity NXGL GlobeNewswire
Mar-25	NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st NXGL GlobeNewswire
Mar-12	NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products NXGL +16.21% GlobeNewswire
Mar-10	NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products NXGL -15.77% GlobeNewswire
Feb-10	NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence NXGL GlobeNewswire
Dec-16	NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor NXGL GlobeNewswire
Dec-11	NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx NXGL +22.67% GlobeNewswire
Nov-11	NEXGEL Reports Third Quarter 2025 Financial Results NXGL NXGL -11.40% GlobeNewswire
Nov-03	NEXGEL to Report Third Quarter 2025 Financial Results on November 11th NXGL GlobeNewswire
Oct-09	NEXGEL to Present at the LD Micro Main Event XIX Conference on October 19-21 NXGL GlobeNewswire
Aug-12	NEXGEL Reports Second Quarter 2025 Financial Results NXGL NXGL -11.44% GlobeNewswire
Aug-06	NEXGEL to Report Second Quarter 2025 Financial Results on August 12th NXGL -6.96% GlobeNewswire
Aug-05	NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors NXGL +5.00% GlobeNewswire
Aug-01	NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement NXGL +14.23% GlobeNewswire
Jul-14	NEXGEL and STADA AG Announce Expansion of Partnership for North America NXGL -5.20% GlobeNewswire
May-21	NEXGEL to Participate in the 6th Annual CEO Networking Event Hosted by Semco Capital on June 2nd NXGL -5.13% GlobeNewswire
May-13	NEXGEL Reports First Quarter 2025 Financial Results NXGL NXGL -9.15% GlobeNewswire
May-09	NEXGEL to Report First Quarter 2025 Financial Results on May 13th NXGL GlobeNewswire

NEXGEL, INC.

Recent Articles by NEXGEL, INC.

Upgrade your Finviz experience